Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Bright Minds Biosciences Inc. (DRUG)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7979-0.0213 (-2.60%)
At close: 03:49PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.8192
Open0.8172
Bid0.7610 x 1000
Ask0.8875 x 1400
Day's Range0.7601 - 0.8172
52 Week Range0.7600 - 8.9500
Volume2,055
Avg. Volume56,867
Market Cap9.473M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.0350
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for DRUG

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Bright Minds Biosciences Inc.
    Daily – Vickers Top Insider Picks for 06/30/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization

    VANCOUVER, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Dr. Alan Kozikowski will no longer serve in the role of Chief Scientific Officer. “Alan has been with Bright Minds since the beginning, and his leadership was instrumental in shaping our

  • GlobeNewswire

    Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

    -- Review of Phase I ready BMB-101 and upcoming milestones -- -- Webcast to be held on May 19, 2022, 4:00pm ET -- VANCOUVER, British Columbia, May 12, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that the Company will host a symposium with Key Opinion Leaders on Dravet Synd

  • GlobeNewswire

    Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties

    -- Herbert Y. Meltzer, MD; Karl Deisseroth, MD, PhD; Robert C. Malenka, MD, PhD; Michael P. Bogenschutz, MD; and Peter Hendricks, PhD, bring decades of clinical and research expertise in psychiatry, addiction, behavioral health, and pharmacology to guide Company’s development programs -- --Scientific Advisory Board members are affiliated with cutting-edge programs at elite academic and medical institutions -- -- Jan Torleif Pedersen, PhD, MSc, CNS drug specialist, to join Board of Directors -- V

Advertisement
Advertisement